RALEIGH, N.C., U.S.A. (Oct 20, 2006)

Qualyst announced today the appointment of Dr. Jean-Pierre Kinet to its Board of Directors.

"We are extremely honored to have Dr. Kinet join our Board of Directors," said Qualyst President and CEO Scott Neuville. “We look forward to his contributions and input as a member of Qualyst’s Board of Directors.”

Jean-Pierre Kinet, M.D., is presently Professor of Pathology at Harvard Medical School. He also serves as Director of the Division of Allergy and Immunology at the Beth Israel Deaconess Medical Center. Prior to Harvard, Dr. Kinet spent 13 years as an investigator with the National Institutes of Health, eventually rising to the position of Section Head at the National Institute of Allergy and Infectious Diseases. Dr. Kinet has authored over
170 publications, holds 10 issued patents, and is renowned for his discovery and characterization of the genes and proteins that encode the high affinity IgE receptor, a key to triggering allergic reactions. His work in immunology has lead to the generation of novel diagnostic tools and therapeutic approaches.

About Qualyst, Inc.
Qualyst commercializes novel and proprietary ADMET products for drug discovery and development. Qualystís products allow pharmaceutical and biotechnology researchers to make faster, better decisions regarding drug candidate compounds, saving valuable time and research dollars in the process. Qualyst, Inc. was founded on discoveries from breakthrough research at the University of North Carolina at Chapel Hill in 2001. For additional information, please refer to the company's web site at www.Qualyst.com or call 919-313-6500.

CONTACT:

Ian J. Mehr
Vice President, Business Development
Qualyst, Inc.
(919)313-6507
info[AT]qualyst[DOT]com
www.Qualyst.com